Results 211 to 220 of about 273,161 (350)

Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies

European Journal of Haematology, EarlyView.
ABSTRACT PD‐1 inhibitors have reshaped the treatment landscape of classical Hodgkin lymphoma, yet a substantial proportion of patients exhibit primary or acquired resistance driven by tumor‐intrinsic alterations, immunosuppressive microenvironmental signals, metabolic constraints, and EBV‐mediated modulation.
Santino Caserta, Enrica Antonia Martino, Mamdouh Skafi, Maria Eugenia Alvaro, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

European Journal of Haematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients.
Mamdouh Skafi, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Fortunato Morabito, Enrica Antonia Martino, Massimo Gentile   +12 more
wiley   +1 more source

Trends and disparities in Non-Hodgkin Lymphoma related mortality in the United States, 1999-2020. [PDF]

PLoS One
Saad M, Aisha E, Sohail MU, Sajid M, Ahmed SZ, Ibrahim ZS, Waqas SA, Aamer H, Makda FA, Aamir J, Afridi MK, Ahmed R.   +11 more
europepmc   +1 more source

Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma

European Journal of Haematology, EarlyView.
ABSTRACT Objectives CAR‐T cell therapies such as lisocabtagene maraleucel (liso‐cel) have transformed the treatment of patients with second line primary refractory or early relapsed ≤ 12 months (R/R) large B‐cell lymphoma (LBCL). The objective of this study was to assess the cost‐effectiveness of liso‐cel compared to standard of care (SOC) to treat R/R
Catherine Thieblemont, Florian Colrat, Rahma Sellami, Marine Sivignon, Adrien Petel, Sébastien Branchoux, Gérard de Pouvourville   +6 more
wiley   +1 more source

The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma. [PDF]

Clin Cancer Res
García-Vicente R, Rodríguez-García A, Ancos-Pintado R, Arroyo A, Ortega-Hernández A, Bragado-García I, Castellano E, Ortiz-Ruiz A, Navarro-Aguadero MÁ, Modrego J, Leivas A, García-Villalba R, Tomás-Barberán FA, Sánchez-Pina JM, Alonso R, Cedena MT, Hernández-Sánchez M, Carpio C, Barba P, Carbonell D, Kwon M, Bastos-Oreiro M, Martín García-Sancho A, Jiménez-Ubieto A, Valeri A, Gómez-Garre D, Martínez-López J, Linares M.   +27 more
europepmc   +1 more source

Silent pressure: Unveiling spinal lymphoma in horses and its parallels to other species

Equine Veterinary Education, EarlyView.
Summary Though the nervous system is an uncommon location for lymphoma, the disease should remain a differential diagnosis in some cases of ataxia in equids. Diagnosis of lymphoma can be challenging, although a combination of cytology, histopathology and immunophenotyping can aid in definitive diagnosis and therefore more accurately guide treatment and
H. E. Taylor, D. Luethy
wiley   +1 more source

Primary non-Hodgkin lymphoma in the muscle of left lower extremity: a case report and literature review. [PDF]

Front Oncol
Du H, Zhang Y, Zhou H, Huo X, Xu M, Xu W.   +5 more
europepmc   +1 more source

New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy

Expert Review of Anticancer Therapy, 2015
Dai Chihara, L. Nastoupil, Jessica N. Williams, Paul Lee, J. Koff, C. Flowers   +5 more
semanticscholar   +1 more source

Next‐generation sequencing‐based IG clonality analysis to discriminate reactive infiltrates from minimal lymphoma involvement in paired lymphoma and bone marrow biopsies; a EuroClonality‐NGS Working Group study

Histopathology, EarlyView.
Next‐generation sequencing (NGS) immunoglobulin clonality analysis can help resolve ambiguous bone marrow staging biopsies for B‐cell lymphoma. In this study, paired analysis of the primary lymphoma and bone marrow helped to detect lymphoma involvement in cases with inconclusive morphology and immunohistochemistry, making it a valuable tool for ...
Michiel van den Brand, Meilinde Leenders, Jos Rijntjes, Jeroen A.C.W. Luijks, Anton W. Langerak, Konnie M. Hebeda, Patricia J.T.A. Groenen   +6 more
wiley   +1 more source

A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma. [PDF]

Clin Cancer Res
Strati P, Feng L, Tyshevich A, Shavronskaya D, Alesse J, English N, Sheehan E, Syzrantsev N, Nesmelov A, Zhuang TZ, Chihara D, Westin JR, Ahmed S, Fayad LE, Henderson J, Dent K, McChesney E, Neelapu SS, Flowers CR.   +18 more
europepmc   +1 more source